The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression

Zhenze Zhao, Spencer D. Shelton, Alejandro Oviedo, Amy L. Baker, Collin P. Bryant, Soroush Omidvarnia and Liqin Du*

Abstract

Background: The oncogene MYCN is critical for tumorigenesis of several types of cancers including neuroblastoma. We previously reported that miR-506-3p repressed MYCN expression in neuroblastoma cells. However, the mechanism underlying such regulation was undetermined since there is no miR-506-3p target site in MYCN 3′UTR.

Methods: By a systematic investigation combining microarray, informatics and luciferase reporter assay, we identified that the transcriptional factor pleiomorphic adenoma gene-like 2 (PLAGL2) is a direct target of miR-506-3p that mediates its regulation on MYCN expression. Using CHIP-PCR and luciferase reporter assay, we validated the transcriptional regulation of MYCN by PLAGL2 and we further demonstrated the transcriptional regulation of PLAGL2 by MYCN. We examined the function of PLAGL2 in regulating neuroblastoma cell fate by cell viability assay, colony formation and Western blotting of differentiation markers. We examined the effect of retinoic acid, the differentiation agent used in neuroblastoma therapy, on miR-506-3p, PLAGL2 and MYCN expressions by quantitative PCR and Western blots. We investigated the clinical relevance of PLAGL2 expression by examining the correlation of tumor PLAGL2 mRNA levels with MYCN mRNA expression and patient survival using public neuroblastoma patient datasets.

Results: We found that miR-506-3p directly down-regulated PLAGL2 expression, and we validated a PLAGL2 binding site in the MYCN promoter region responsible for promoting MYCN transcription, thereby establishing a mechanism through which miR-506-3p regulates MYCN expression. Conversely, we discovered that MYCN regulated PLAGL2 transcription through five N-Myc-binding E-boxes in the PLAGL2 promoter region. We further confirmed the reciprocal regulation between endogenous PLAGL2 and MYCN in multiple neuroblastoma cell lines. Moreover, we found that PLAGL2 knockdown induced neuroblastoma cell differentiation and reduced cell proliferation, and combined knockdown of PLAGL2 and MYCN showed a synergistic effect. More strikingly, we found that high tumor PLAGL2 mRNA levels were significantly correlated with high MYCN mRNA levels and poor patient survival in neuroblastoma patients. Furthermore, we found that retinoic acid increased expression of miR-506-3p and repressed expression of MYCN and PLAGL2.

Conclusions: Our findings altogether suggest that the interplay network formed by PLAGL2, MYCN and miR-506-3p is an important mechanism in regulating neuroblastoma cell fate, determining neuroblastoma prognosis, and mediating the therapeutic function of retinoic acid.

Keywords: miR-506-3p, Neuroblastoma, PLAGL2, MYCN, Retinoic acid, Cell differentiation
Background
It is well known that aberrant expression of the MYCN gene, which encodes the transcription factor (TF) N-Myc, plays a key role in neuroblastoma tumorigenesis [1–6]. One of the well-characterized mechanisms that lead to MYCN overexpression in neuroblastoma is MYCN gene amplification, which is observed in 25% of neuroblastomas and is associated with poor patient prognosis [3, 7]. Experimental demonstration for the critical role of MYCN in neuroblastoma was from MYCN transgenic mouse models in which neuroblastoma spontaneously developed [8]. The above evidence supports that blocking MYCN expression would be beneficial for neuroblastoma patients. However, N-Myc protein currently remains largely undruggable as its active DNA-binding domain is composed of two extended alpha helices with no apparent surfaces for small molecule binding [9]. The mechanisms that drive MYCN overexpression at transcriptional and post-transcriptional levels have been recognized. These levels of regulatory mechanisms possibly provide paths to target the MYCN pathway for therapy, if druggable molecules are identified in its regulatory network.

One of the regulatory mechanisms of MYCN expression is found at the transcription level. For example, E2F and Sp1/Sp3 binding sites were identified in the MYCN promoter, and the activation of the MYCN promoter required cooperative binding of these TFs to the promoter [10, 11]. However, E2F and Sp1/Sp3 were not sufficient to activate the MYCN gene expression [11], indicating additional requirements for its transcriptional activation. Additional transcription mechanisms have been investigated [12–15]. One such mechanism was demonstrated by Schonnerr et al., showing that anaplastic lymphoma kinase (ALK) was involved in initiating the transcription of MYCN in neuroblastoma cells [15], providing a potential therapeutic path to block the oncogenic function of MYCN. However, elevated ALK activity occurs only in around 14% of high-risk neuroblastoma [16], suggesting that MYCN is not targetable through the ALK pathway in the majority of neuroblastoma cases. Overall, even though the knowledge on the mechanisms of MYCN transcriptional regulation has been advanced in recent years, the regulatory complex of MYCN transcription is far from being fully defined. Further elucidation of its transcriptional mechanisms would benefit the development of novel approaches to target the MYCN pathway.

Another class of regulators of MYCN expression is microRNAs (miRNAs). Multiple miRNAs have been identified to regulate MYCN expression either by directly targeting the 3’ untranslated region (3’UTR) of MYCN mRNA or through indirect pathways [17–19]. Our group previously identified miR-506-3p as a potent differentiation inducer and a strong repressor of MYCN expression in neuroblastoma cells [17, 20]. However, MYCN is not a direct target of miR-506-3p and the mechanism of its regulation by miR-506-3p was not determined in the previous study [17]. In this study, we demonstrate that miR-506-3p directly targets the 3’UTR of Pleiomorphic adenoma gene like-2 (PLAGL2), and the latter functions as an activator of MYCN transcription through a PLAGL2 binding site in the MYCN promoter, unraveling the mechanism by which miR-506-3p regulates MYCN expression.

On the other hand, N-Myc is known to regulate transcription of many genes involved in a variety of biological processes including cell differentiation [21, 22]. Here we investigated the transcriptional regulation of PLAGL2 by N-Myc in neuroblastoma cells. Furthermore, cell differentiation has been well known to play a key role in neuroblastoma tumorigenesis and differentiation therapy [3, 23]. Neuroblastoma cell differentiation is triggered by certain signals, including repression of MYCN expression [4, 24, 25], overexpression of tumor suppressive miRNAs [20, 26, 27], and pharmacological concentrations of differentiation agent retinoic acid (RA) [28]. Therefore, following the discovery of the interplay between PLAGL2, MYCN and miR-506-3p, we further investigated the function of PLAGL2 in regulating neuroblastoma cell differentiation and the possible involvement of this interplay network in mediating the cellular function of RA, and investigated the clinical relevance of PLAGL2 in determining neuroblastoma prognosis.

Materials and methods
Cell lines and materials
The human neuroblastoma cell lines BE(2)-C, SKNDZ, IMR322, SKNFL, SKNB [2], CHP212, SKNMC, SKNAS, MCIXC, and SKNSH were obtained from American Type Culture Collection (Manassas, VA, USA); CHLA-90 and COG-N-322 (N322) were from Children’s Oncology Group (Monrovia, CA, USA); KELLY and NGP were from the cell line repository at the Greehey Children’s Cancer Research Institute at the University of Texas Health San Antonio. HEK 293T cells were from Thermo Fisher Scientific (Hampton, NH, USA). Cells were cultured in DMEM/F12 (Corning Inc., Corning, NY, USA) with 10% Equafetal bovine serum (Atlas Biologicals, Fort County, CO, USA). miR-506-3p mimic, siRNAs and negative control oligos were purchased from Dharmaco (Lafayette, CO, USA). PCR Primers were designed in-house (sequences are listed in Additional file 1: Table S1) and purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit anti-N-Myc (α-N-Myc), anti-PCNA, anti-Ki67, anti-cleaved PARP, anti-calnexin, and HRP-conjugated anti-rabbit IgG antibodies were from Cell Signaling Technology (Danvers, MA, USA). Rabbit anti-PLAGL2 (α-PLAGL2) antibody was from MyBioSource.
Total RNA was isolated using Trizol reagent. 2 μg RNA was reverse transcribed using Superscript II and random primers (Applied Biosystems, Waltham, MA, USA). An aliquot of cDNA corresponding to 50 ng of RNA was used for running SYBR Green-based qPCR analysis using ABI 7000.

**Western blots**

Cell lysate collection, SDS-PAGE gel electrophoresis, transfer to PVDF membranes, and Western blotting were performed as previously described [29]. For quantitative comparison between treatment groups, the raw band intensities in the Western blot images were quantified using Image J, and the relative band intensities were derived as the following: the raw band intensity of a specific protein in a specific treatment group was first normalized to its corresponding loading control (i.e., calnexin). Then the calnexin-normalized band intensity in the treatment group was further normalized to that in the control group. For example, for analyzing the effect of miR-506-3p mimic on N-Myc protein expression, the raw N-Myc band intensity in each treatment group was first normalized to the raw band intensity of the calnexin blot in the corresponding treatment group, and then the calnexin-normalized N-Myc band intensity in the miR-506-3p mimic treatment group were further normalized to that in the control oligo group to obtain the final relative intensity.

**Chromatin immunoprecipitation-PCR (CHIP-PCR)**

CHIP-PCR was used to validate the binding of PLAGL2 and MYCN proteins to their predicted binding sites in the corresponding promoter regions. CHIP was performed according to published procedures with modifications [10]. Briefly, four 10-cm dishes of sub-confluent cells were cross-linked with 1% formaldehyde. Cells were collected in lysis buffer (5 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% deoxycholate, 0.1% SDS, and protease inhibitors). After incubation on ice for 10 min, the solution was sonicated with a Tissue Tearor Homogenizer (Cole-Parmer, Cernon Hills, MI, USA) at half maximum power for ten 10-s pulses on ice. The chromatin solution was centrifuged, and the supernatant was then pre-cleared with protein A/G agarose beads (Santa Cruz Biotech, Santa Cruz, CA, USA). Aliquots of the pre-cleared chromatin were incubated with 2 μg antibody overnight at 4 °C. One aliquot (100 μl) was incubated without antibody (this sample is referred to as Input). Immune complexes were captured with 40 μl of BSA-blocked protein A/G agarose, and then digested with RNase A and proteinase K. The co-precipitated DNA was isolated using PCR purification column (Qiagen, Germantown, MD, USA). 1 μl of the isolated DNA was used for PCR.

**pmiRGLO 3’UTR luciferase reporter assay**

The pmiRGLO 3’UTR Luciferase reporter assay was used to validate the target site of miR-506-3p in the
3′UTR in the PLAGL2 mRNA. To generate the wildtype luciferase reporter (PLAGL2-WT) for the predicted miR-506-3p target site in the 3′UTR of PLAGL2, a fragment of the PLAGL2 3′UTR (3008 bp to 3671 bp) containing the predicted target site (UGCCUUA) of miR-506-3p was amplified from human genomic DNA by PCR using Phusion enzyme (New England Biolabs, Ipswich, MA, USA) and inserted downstream of firefly luciferase coding sequence (CDS) in the pmirGLO dual-luciferase reporter (Promega, Madison, WI, USA) using In-Fusion cloning kit (Takara Bio USA, Mountain View, CA, USA). Mutant reporter (PLAGL2-MU) with mutated seed sequence (CCUCAGA) at predicted target site was generated by site-directed mutagenesis using high fidelity DNA polymerase (Agilent Technologies, Santa Clara, CA, USA). BE(2)-C cells were co-transfected with pmirGLO luciferase reporter and miR-506-3p for 2 days, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) in a BioTek Synergy H4 microplate reader.

pGL3B promoter luciferase reporter assay

The pGL3B promoter luciferase reporter assay was used to validate the function of the PLAGL2- and MYCN-binding DNA sequences in regulating gene transcription. The putative PLAGL2 binding site in the MYCN gene promoter region and the N-Myc-binding E-boxes in the PLAGL2 gene promoter region were predicted using ConTra V3 prediction tool. A DNA fragment from the wildtype MYCN (~480 bp to ~124 bp) promoter region containing the putative PLAGL2 binding site (CCCCCGGAGCCCTC) was amplified and inserted upstream of firefly luciferase gene in the pGL3B reporter vector (Promega) between Sac I and Hind III cloning sites to generate the wildtype reporter (mycPWT-Luc). Mutant pGL3B reporter (mycPMU-Luc) containing mutated binding site (CCTCAGCTCCACTC) was generated as above. For the N-Myc-binding E-boxes in PLAGL2 gene promoter, DNA fragments from the PLAGL2 promoter region containing different combinations of the 5 putative E-boxes were amplified and inserted into pGL3B luciferase reporter to generate three reporter vectors, plaP(E1–5)Luc reporter which contains all five E-boxes (~640 bp to ~28 bp), plaP(E1–3)Luc which contains E1 to E3 E-boxes (~445 bp to ~28 bp), and plaP(E4–5)Luc which contains E4 and E5 E-boxes (~640 bp to ~429 bp). A reporter without an insert was used as a negative control. 293T cells were co-transfected with either PLAGL2 or MYCN expression vectors and pGL3B reporter vectors. After 72 hours, cell lysates were harvested, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) in a BioTek Synergy H4 microplate reader.
Fig. 2 (See legend on next page.)
mRNA expression array

mRNA expression array was conducted to examine the effect of miR-506-3p overexpression on gene expression as previously reported [20]. Total RNA was isolated using the miRVana miRNA isolation kit (Life Technologies, Carlsbad, CA, USA) as previously reported [30]. mRNA expression profiling was performed using the Illumina mRNA WG-6 v3 microarray platform as previously reported [20].

Neuroblastoma patient survival analysis and tumor gene expression correlation analysis

The analyses were performed to examine the clinical relevance of PLAGL2 expression in neuroblastoma tumors, and were conducted using three published neuroblastoma patient datasets in the R2: Genomics Analysis and Visualization Platform [31], the Kocak (649 patients), SEQC (498 patients) and NRC (283 patients) datasets. Patient survival analyses were conducted using the Kaplan-Meier method offered by the R2 platform. In detail, the neuroblastoma patients were first divided into two groups based on the analysis of the overall patient survival by using the Kaplan Scan (Scan) cutoff modus offered by the R2 program, where an optimum survival cutoff was established based on statistical testing. Specifically, in the order of the patient tumor PLAGL2 mRNA expression, the Scan module uses every increasing expression value as a cutoff to create two groups (i.e., the high and low PLAGL2 mRNA groups) and test the $p$-value in a log rank test, and then the most significant expression cutoff for the overall survival analysis is identified. The overall and event-free Kaplan-Meier survival curves for the two identified groups are then derived.

The statistical significance of the difference in PLAGL2 mRNA levels between the two groups were examined by unpaired t-test, with $p < 0.05$ considered as statistically significant. The statistical significance of difference in survival between groups was determined by 2-tailed log-rank test with $p < 0.05$ considered statistically significant. Correlations between MYCN mRNA levels and PLAGL2 mRNA levels were assessed by Pearson correlation, with $p < 0.05$ considered statistically significant.

Other statistical analyses

To evaluate the effect of treatments, the statistical significance of difference between each treatment and the control group was determined by two-tailed Student’s $t$-test, with $p < 0.05$ considered statistically significant. The synergistic effect of combined treatment on cell viability was evaluated based on the Bliss Independence model, which defines the predicted additive effects of the two treatment groups by $E_{xy} = E_x + E_y - E_xE_y$, where $E_x$ and $E_y$ are the effects of the individual treatments of X and Y on cell viability [32].

Results

miR-506-3p has a generic effect in down-regulating MYCN expression in neuroblastoma cell lines

We previously found that miR-506-3p down-regulated MYCN expression in three neuroblastoma cell lines [17]. Here we further investigated the function of miR-506-3p in regulating MYCN expression in additional neuroblastoma cell lines with distinct genetic backgrounds (Additional file 2: Table S2). As shown in Fig. 1a, miR-506-3p overexpression significantly down-regulated MYCN expression at mRNA levels in all fourteen cell lines. Figure 1b further shows that miR-506-3p dramatically down-regulated N-Myc protein expression in ten cell lines. Although the N-Myc levels were not detectable in four MYCN non-amplified cell lines (SKNMC, SKNAS, MCIIXC and SKNSH) using currently
Fig. 3 (See legend on next page.)
available antibodies, results in Fig. 1a clearly show that miR-506-3p effectively down-regulated MYCN expression at mRNA levels in these cells. These results confirm that miR-506-3p mimic has a generic effect in down-regulating MYCN expression in neuroblastoma cells regardless of the MYCN amplification status and other genetic backgrounds.

**PLAGL2 is identified as a direct target of miR-506-3p that regulates transcription of MYCN gene**

Since there is no miR-506-3p target site in the 3'UTR of MYCN, we speculate that miR-506-3p directly targets a TF that promotes MYCN expression. We combined expression microarray analysis with informatics analysis and literature search to systematically identify putative TFs that are down-regulated by miR-506-3p, predicted to be direct targets of miR-506-3p, and also predicted to transcriptionally regulate MYCN expression. As shown in Fig. 2a, we first exploited expression array to identify genes with their expression down-regulated by ≥40% following transfection of BE(2)-C cells with miR-506-3p mimic for 24 h (Tier 1), which yielded 225 genes. We then combined Ingenuity Pathway Analysis (IPA) and PubMed literature search to identify the TFs among the 225 genes (Tier 2, yielded 11 genes). Finally, we exploited the published TargetScan program [33] to identify TFs that are predicted to be direct targets of miR-506-3p (Tier 3), which yielded two TFs, PLAGL2 and CREB3L2. Additional file 3: Table S3 and Additional file 4: Table S4 shows the predicted target sites of miR-506-3p in the 3'UTRs of the two TFs and the extent of down-regulation of their mRNAs by miR-506-3p detected in the expression microarray, respectively. We further confirmed the down-regulation of PLAGL2 and CREB3L2 mRNAs by miR-506-3p in independent experiments in two cell lines (Fig. 2b).

To determine whether PLAGL2 and CREB3L2 regulate MYCN expression, we transiently knocked down PLAGL2 and CREB3L2 expression using siRNAs in two cell lines. As shown in Fig. 2c, siPLAGL2 but not siCREB3L2 significantly decreased both MYCN mRNA and N-Myc protein levels. Two additional siRNAs designed to target different sites of the PLAGL2 transcript confirmed the decrease of N-Myc expression by PLAGL2 knockdown (Fig. 2d), excluding the possibility of off-target effect of siPLAGL2s on MYCN expression. We further examined the effect of PLAGL2 knockdown on MYCN expression at mRNA level in three MYCN non-amplified cell lines. As shown in Fig. 2e, siPLAGL2 significantly down-regulated MYCN mRNA levels in all three cell lines; the depletion of PLAGL2 protein by siPLAGL2 was confirmed in parallel (Fig. 2f). In addition, we showed that over-expression of PLAGL2 in a MYCN non-amplified cell line SKNSH increased MYCN mRNA levels and compromised the extent of MYCN down-regulation by miR-506-3p (Fig. 2g), although the up-regulation of MYCN expression by PLAGL2 was not detectable at protein level. These results altogether indicate that the regulation of MYCN expression by PLAGL2 is a generic mechanism in neuroblastoma cells.

To confirm the target site of miR-506-3p in the 3'UTR of PLAGL2 mRNA, wildtype (PLAGL2-WT) and mutated (PLAGL2-MU) luciferase reporters were constructed (Fig. 2h). As shown in Fig. 2i, miR-506-3p mimic significantly decreased luciferase activity in cells expressing PLAGL2-WT comparing to control oligo, whereas it did not significantly decrease luciferase activity in cells expressing PLAGL2-MU. These results indicate that the predicted target site of miR-506-3p in the 3'UTR of PLAGL2 truly mediates the down-regulation of PLAGL2 expression by miR-506-3p.

**PLAGL2 promotes MYCN transcription by directly binding to a specific sequence upstream of the CDS of MYCN gene**

We identified a putative PLAGL2 binding site at the 378-nucleotide position upstream of the MYCN CDS (Fig. 3a). To examine whether this is a functional regulatory site of PLAGL2, wildtype (mycPWT-Luc) and mutated (mycPMU-Luc) luciferase reporters were constructed (Fig. 3a). Each reporter was transfected into HEK 293T cells together with a PLAGL2 over-expression vector (PLAGL2) or a
Fig. 4 (See legend on next page.)
control expression vector (Control). As shown in Fig. 3b, PLAGL2 overexpression significantly increased luciferase activity in mycPWT-Luc cells, but not in mycPMU-Luc cells, comparing to their corresponding controls. These results indicate that the predicted binding site is a true target site of PLAGL2 that regulates transcription.

To further examine whether PLAGL2 directly binds to the above sequence, CHIP-PCR was performed in two cell lines. Figure 3a illustrates the positions of the DNA sequences to be amplified by each PCR primer sets, with primer 1 used to amplify the predicted PLAGL2-binding sequence and primer 2 used as a negative control. As shown in Fig. 3c, anti-PLAGL2 antibody (α-PLAGL2) successfully pulled down the predicted PLAGL2-binding sequence but not the control sequence. In addition, non-specific IgG did not pull down any of the above sequences, excluding the possibility of non-specific pull-down of protein-DNA complexes by IgGs. Furthermore, the predicted PLAGL2-binding sequence was not pulled down by α-PLAGL2 antibody in cells with PLAGL2 expression depleted by siPLAGL2, further supporting the specificity of the assay. The extent of PLAGL2 protein depletion by siPLAGL2 was confirmed by Western blots (Fig. 3d). Together, these results demonstrate that PLAGL2 activates MYCN transcription through directly binding to the identified PLAGL2-binding sequence in the promoter region of MYCN.

N-Myc promotes PLAGL2 transcription through multiple binding sites in the PLAGL2 promoter region

Since N-Myc is known to regulate transcription of many genes, we were curious about its role in regulating PLAGL2 transcription. Remarkably, we found five putative N-Myc binding E-boxes upstream of PLAGL2 CDS (Fig. 4a). To test whether these E-Boxes are true N-Myc binding sites, segments of DNA sequences containing the indicated E-Boxes were amplified to construct three reporters, the plaP(E1–5)−Luc, plaP(E4–5)−Luc and plaP(E1–3)−Luc (Fig. 4a). A reporter with no insertion was used as a negative control (Control). Each reporter was co-transfected with a MYCN overexpression vector (MYCN (+)) or a control expression vector (MYCN (−)) as shown in Fig. 4b. MYCN overexpression resulted in a significant increase of luciferase activity in cells expressing the plaP(E1–5)−Luc, plaP(E4–5)−Luc and plaP(E1–3)−Luc but not in cells expressing the Control reporter. The luciferase expression from plaP(E1–3)−Luc, which contains all five E-Boxes, was increased most dramatically. We further exploited CHIP-PCR to examine the direct binding of N-Myc to the predicted sites using the primer sets shown in Fig. 4c, with primers 1–3 designed to amplify the sequence containing the indicated E-boxes and primer 4 designed as a negative control. As shown in Fig. 4d, primers 1, 2 and 3 successfully amplified their corresponding PCR products from the DNAs pulled down by α-N-Myc antibody. In contrast, IgG pulldown and primer 4 did not yield any PCR product, confirming that N-Myc specifically bind to the examined E-boxes.

N-Myc regulates endogenous expression of PLAGL2

We next investigated whether N-Myc regulate endogenous expression of PLAGL2 in a panel of neuroblastoma cell lines. As shown in Fig. 5a, siMYCN significantly decreased PLAGL2 mRNA levels in all eight cell lines. Correspondingly, PLAGL2 protein levels were also dramatically decreased by siMYCN (Fig. 5b). In addition, over-expression of MYCN by a MYCN expression vector in three MYCN non-amplified cell lines dramatically increased PLAGL2 mRNA expression (Fig. 5c), further demonstrating the transcription activation of PLAGL2 by N-Myc. Altogether, the above results indicate that miR-506-3p, PLAGL2 and MYCN form an interplay network in neuroblastoma cells.

RAs upregulate miR-506-3p expression and downregulate the expression of both PLAGL2 and MYCN

Differentiation agents RAs have been used for neuroblastoma therapy for decades [34, 35]. The mechanism by which RAs induce neuroblastoma cell differentiation, however, has not been fully elucidated. Here we investigated the possible involvements of the miR-506-3p, PLAGL2 and MYCN in RA signaling. As shown in Fig. 6a-d, both ATRA and 13-cis-RA (5 μM) significantly decreased the expression of MYCN and PLAGL2 at mRNA and protein levels, and significantly increased the expression of miR-506-3p, in a time-dependent manner. In addition, both RAs also showed a dose-dependent effect on MYCN, PLAGL2 and miR-506-3p expressions.
Fig. 5 MYCN regulates endogenous expression of PLAGL2 in neuroblastoma cells. a-b Effect of MYCN knockdown on PLAGL2 mRNA and protein levels. Cells were transfected with siMYCN or siControl at 25 nM for 2 days. PLAGL2 mRNA (a) and protein (b) levels were detected as above. c Effect of MYCN overexpression on PLAGL2 expression in MYCN non-amplified neuroblastoma cells. Cells were transfected with a MYCN over-expression vector or a control vector for 2 days. The levels of N-Myc protein and PLAGL2 mRNA were detected as above. *, p < 0.05, comparing to control. Protein levels in the Western blot images were quantified as above.
Fig. 6 (See legend on next page.)

**A**

![Graph A](image1)

**B**

![Graph B](image2)

**C**

![Graph C](image3)

**D**

![Graph D](image4)

**E**

![Graph E](image5)

**F**

![Graph F](image6)

**G**

![Graph G](image7)

**H**

![Graph H](image8)

**I**

![Graph I](image9)

**J**

![Graph J](image10)
PLAGL2 knockdown on neurite outgrowth in BE(2)-C cells. Correspondingly, it decreased expression in neuroblastoma cells. As shown in Fig. 7a, cells have not been fully defined previously. Here we in-

Knockdown of PLAGL2 induces differentiation, reduces survival and proliferation of neuroblastoma cells

The cellular functions of PLAGL2 in neuroblastoma cells have not been fully defined previously. Here we investigated the cellular responses to the aberrant PLAGL2 expression in neuroblastoma cells. As shown in Fig. 7a, knocking down PLAGL2 significantly decreased cell survival, with the extent of decrease by siPLAGL2 being similar to that caused by siMYCN. Combined knock-
down of MYCN and PLAGL2 showed robust synergistic effect, with the actual remaining cell viability of the combined treatment (0.172 ± 0.005) being dramatically lower than the predicted remaining viability due to additive effects (0.353). In parallel, the effect of the above treatments on PLAGL2 and MYCN protein expressions were confirmed (Fig. 7b). Due to the semi-quantification nature of the Western blotting approach, the synergistic effect at the protein level was not determined. In addition, Fig. 7c shows that siPLAGL2 reduced cell proliferation rate comparing to siControl, as measured by cell confluence change over time. Figure 7d further shows that siPLAGL2 decreased colony formation of BE(2)-C cells relative to siControl. Furthermore, siPLAGL2 increased expression of neuronal differentiation markers βIII-tubulin, growth associated protein 43 (GAP43) and neuron specific enolase (NSE) (Fig. 7e), indicating cell differentiation is induced. Correspondingly, it decreased expres-
sions of cell proliferation markers proliferating cell nuclear antigen (PCNA) and Ki67, and increased expression of apoptosis marker cleaved Poly (ADP-ribose) polymerase (CL PARP) (Fig. 7e). We further examined the effect of PLAGL2 knockdown on neurite outgrowth in BE(2)-C cells. As shown in Fig. 7f-g, siPLAGL2 dramatically and significantly induced neurite outgrowth comparing to control oligo. These results altogether support the function of PLAGL2 in regulating neuroblastoma cell differentiation and proliferation.

High tumor PLAGL2 mRNA levels are correlated with high tumor MYCN mRNA levels and poor survival of neuroblastoma patients

To evaluate the clinical relevance of PLAGL2 in neuroblastoma patients, we examined the correlation of PLAGL2 mRNA expression with MYCN mRNA levels in neuroblastoma patients as well as its correlation with patient survival based on published neuroblastoma patient datasets [31]. As shown in Fig. 8a-c, significant positive correlation between PLAGL2 and MYCN mRNA levels were observed in all three datasets, suggesting that the positive regulatory loop formed between PLAGL2 and MYCN play a critical role in controlling the expression of each other in neuroblastoma tumors. To examine the correlation of tumor PLAGL2 mRNA levels with neuroblastoma patient survival, the patients were classified by PLAGL2 mRNA levels into high or low PLAGL2 groups in each dataset (Fig. 8d-f). Patient survival analysis indicates that both the overall (Fig. 8g-i) and event-free survivals (Fig. 8j-l) in the high PLAGL2 groups are significantly lower than those in the low groups based on both the raw and adjusted Bonferroni p values in all three datasets, suggesting that elevated PLAGL2 expression is an important mechanism to drive the poor prognosis of neuroblastoma patients.

Discussion

In this study, we characterized a novel interaction network involved in regulating neuroblastoma cell differen-
tiation and potentially determining the clinical prognosis of neuroblastoma (Fig. 9). The highlight of our finding is that we demonstrate for the first time that PLAGL2, a TF that has previously been recognized as an important regulator of cell fate [36], plays a key role in modulating neuroblastoma cell differentiation via interacting with three well-recognized differentiation-regulating molecules of neuroblastoma cells, MYCN, RA and miR-506-3p [17, 20, 37, 38]. In addition, we found that RAs
Fig. 7 (See legend on next page.)
regulate expressions of all the other three molecules in the network, indicating that this interplay network is a pathway mediating the therapeutic mechanism of RAs.

PLAGL2 belongs to the PLAG family of C2H2 zinc finger TFs [39, 40]. Two members in the family, PLAG1 and PLAGL2, were found to be cell growth promoting and oncogenic in several cancer cell types [41–44]. More relevant to our current study, Zheng et al. found that enforced PLAGL2 expression in neuronal stem cells and glioma initiating cells strongly impeded cell differentiation [36]. This is consistent with our findings showing that knocking down PLAGL2 expression induced neuroblastoma cell differentiation and inhibited cell proliferation. Together these findings strongly support that PLAGL2 plays a critical role in maintaining the proliferative and undifferentiated status of cells of neuronal origin, including neuroblastoma cells. In the investigation of the mechanism that mediates such function of PLAGL2, Zheng et al. showed that PLAGL2 impeded differentiation of neural stem cells and glioma initiating cells through modulating Wnt signaling [36]. Here we demonstrate for the first time that PLAGL2 directly regulates the transcription of MYCN, the well-known key regulator of neuroblastoma cell differentiation, disclosing a previously unknown mechanism underlying the differentiation-regulating function of PLAGL2. Given the demonstrated oncogenic relevance of MYCN in many types of cancers [45], whether the PLAGL2-MYCN axis is also a key player in modulating cell differentiation and proliferation in other cancer types is certainly an interesting question to address in the future. Additional transcriptional targets of PLAGL2 (e.g., MPL and ASCL2) were found in other cancer cell types [46, 47]. Given the complexity of the PLAGL2 transcriptome indicated in the published studies, it is reasonable to speculate that MYCN is not the sole transcription target that mediates the function of PLAGL2 in neuroblastoma cells. Moreover, a recent study reported a function of PLAGL2 other than acting as a TF [48], which showed that PLAGL2 modulates the stability of pirh2 through direct binding to pirh2 [48]. Also interestingly, the 3’UTR of PLAGL2 was found to be independently overexpressed in colorectal cancer cells, and has an independent function in regulating C-Myc and CD44 expression and in promoting cell proliferation and tumor growth [49]. Whether these non-TF functions of PLAGL2 play a role in modulating neuroblastoma cell fate certainly warrants future investigation.

We discovered that PLAGL2 expression is regulated by MYCN at the transcription level in neuroblastoma cells. As a key regulator of neuroblastoma cell fate, whether PLAGL2 transcription is regulated by other TFs, especially TFs that are relevant in neuroblastoma tumorigenesis, is certainly a key question that needs to be addressed. PLAGL2 expression has also been shown to be regulated at the translational and post-translational levels. One mechanism is through increasing the stability of PLAGL2 mRNA, which is reported by Su et al [49]; this study showed that the HuR protein stabilized PLAGL2 mRNA by binding to its 3’UTR, and subsequently caused an increase in PLAGL2 protein expression [49]. The regulation of PLAGL2 expression by miRNAs has also been reported. For example, miR-214 was found to target the 3’UTR of PLAGL2 mRNA and down-regulated PLAGL2 expression in neuroblastoma cells [50]. miR-449a, miR-486-5p and let-7 were found to target the 3’UTR of PLAGL2 mRNA in other cancer cell types [46, 49, 51, 52]. Here we identified for the first time PLAGL2 as a direct target of miR-506-3p in neuroblastoma cells, expanding the miRNA regulatome of PLAGL2 expression. Additional mechanisms that regulate PLAGL2 expression and functions, including gene amplification and DNA insertion [44, 49], post-translational modifications of PLAGL2 protein [53, 54] and regulation of PLAGL2 activity by PLAGL2-binding proteins [55], have been reported in other cell types but have not been investigated in neuroblastoma. Overall, the molecular mechanisms that regulate PLAGL2 expression and function have been demonstrated to be complex, and future effort is certainly needed to fully dissect the molecular network involved in modulating PLAGL2 expression and functions in neuroblastoma.

Another interesting finding in our study is that RAs up-regulate miR-506-3p expression and down-regulate
Fig. 8 Correlation of tumor PLAGL2 mRNA levels with tumor MYCN mRNA levels and patient survival in neuroblastoma patients. (a-c) The correlation of tumor PLAGL2 and MYCN mRNA expression levels in the indicated three public neuroblastoma datasets, Kocak (a), SEQC (b), and NRC dataset (c). Shown in each graph is the correlation coefficient (r) and p-values calculated based on Pearson correlation. (d-f) Patients in the three datasets were grouped into low and high groups based on the tumor mRNA levels of PLAGL2. (g-l) Comparison of Kaplan-Meier overall (g-i) and recurrence-free (j-l) survival curves between the low and high PLAGL2 groups in each dataset.
both MYCN and PLAGL2 expressions. While the downregulation of MYCN by RAs was reported previously [56, 57], we are the first to define the regulation of PLAGL2 and miR-506-3p expressions by RAs. Although RAs have been identified as differentiation agents of cancer cells since 1970s [58–66] and have been used to treat neuroblastoma for decades, the molecular mechanisms underlying such function are still poorly understood. RAs are thought to regulate gene transcriptions by binding to RA receptors RAR and RXR, which are TFs that regulate gene transcriptions by binding to RA response elements (RARE) in the target genes [56]. However, their transcriptional targetome and the downstream signaling involved in regulating neuroblastoma cell differentiation are far from elucidated [37]. Here we found that RA treatments altered expression of all other three molecules in our identified interplay network, suggesting this is at least one of the signaling pathways mediating differentiation-inducing and therapeutic activity of RAs.

Conclusions
In summary, we identified a novel four-molecule interplay network that plays a key role in determining neuroblastoma progression and in mediating the therapeutic function of retinoic acid. This interplay provides a possible mean to develop novel strategies to target the MYCN pathway for treating neuroblastoma. In addition, given the demonstrated oncogenic relevance of MYCN in many types of cancers, we expect that further characterization of this network in other cancer types may lead to the development of novel diagnostic and therapeutic approaches to a broad spectrum of cancers. In the future, mechanisms of interactions between the molecules in the network require further characterization in order to eventually serve the purpose of cancer diagnosis and therapy. In addition, the mechanisms of action of PLAGL2, as a new key player in regulating neuroblastoma cell fate, warrant further investigation.

Supplementary information

Abbreviations
13-cis RA: 13-cis retinoic acid; 3′UTR: 3′ untranslated region; ALK: Anaplastic lymphoma kinase; ATRA: All-trans retinoic acid; CDS: Coding sequence; CHIP-PCR: Chromatin immunoprecipitation-polymerase chain reaction; CL: Cleaved Poly (ADP-ribose) polymerase; CREB3L2: CAMP Responsive Element Binding Protein 3 Like 2; GAP43: Growth Associated Protein 43; IPA: Ingenuity Pathway Analysis; miRNAs: microRNAs; NSE: Neuron-Specific Enolase; Oligo: Oligonucleotides; PCR: Polymerase chain reaction; PCNA: Proliferating cell nuclear antigen; PLAGL2: Pleiomorphic adenoma gene like-2; qPCR: quantitative PCR; RA: Retinoic acid; TF: Transcription factor; WT: Wildtype; α-N-Myc: anti-N-Myc antibody; α-PLAGL2: anti-PLAGL2 antibody

Acknowledgements
No applicable.

Authors’ contributions
ZZ and LD designed the study. ZZ performed most of the experiments and data analysis. SS performed some of the qPCR experiments. AO and AB performed some of the cell viability experiments. CB, SQ and AB performed data analyses. LD wrote the manuscript with the help from all coauthors. All authors read and approved the final manuscript.

Funding
This work was supported by the PRMRP Discovery Award (grant number PR121532) from the Department of Defense (to Liqin Du) and the Startup funds from Texas State University (to Liqin Du).

Availability of data and materials
The datasets used in the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
No applicable.
Competing interests
The authors declare that they have no competing interests.

Received: 5 September 2019 Accepted: 21 January 2020
Published online: 22 February 2020

References
1. Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H. Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development. 1997;124(10):1953–62.
2. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun. 2006;351(1):192–7.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.
4. Henriksen JF, Haug BH, Buechner J, Tomte E, Løkke L, Claegstad T, et al. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Dev Biol. 2011;11:11.
5. Cotterman R, Knoepfler PS. N-Myc regulates expression of pluripotency genes in neuroblastoma including Ift, Mf4, and lin28b. PLoS One. 2009;4(6):e5799.
6. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111–6.
7. Saveleva I, Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 2001;167(2):115–23.
8. Weiss WA, Allday K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes transgenic mice. EMBO J. 1997;16(11):2985–95.
9. Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010;1(6):650–9.
10. Strieder V, Lutz W. E2F proteins regulate MYCN expression in neuroblastomas. J Biol Chem. 2003;278(5):2983–9.
11. Kamps C, Strieder V, Sapetschnig A, Suske G, Lutz W. E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J Biol Chem. 2004;279(7):6110–7.
12. Kaneko Y, Suenaga Y, Islam SM, Matsumoto D, Nakamura Y, Ohta M, et al. Functional interplay between MYCN, MYCIN and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci. 2015;106(7):840–6.
13. Adamek M, McDonald FL, Richert A, Webster A, Varghese R. Functional disruption of the human N-MYC gene in neuroblastoma. Oncogene. 2012;31(50):5193–200.
14. Zhao Z, Ma X, Shelton SD, Sung DC, Li M, Hernandez D, et al. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. Oncotarget. 2016;7(48):79372–87.
15. Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, Lalwani A, et al. Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN. Cancer Res. 2018;78(12):3122–34.
16. Roth SA, Hald GH, Fuchs S, Løkke C, Mikkola I, Claegstad T, et al. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN. Oncotarget. 2018;9(26):18160–9.
17. Zhao Z, Ma X, Hisao TH, Lin G, Kostì A, Yu X, et al. A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. Oncotarget. 2014;5(9):2499–512.
18. Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008;22(20):2755–66.
19. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90.
20. Park JR, Eggett A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):165–86.
21. Negroni A, Scapar S, Romero A, Ferrari S, Modesti A, Raschella G. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ. 1991;2(10):511–8.
22. Tonelli R, Purgato S, Camerini C, Fronza R, Bologna F, Alboresi S, et al. Antigen peptide nuclear acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther. 2005;4(5):779–86.
23. Zhao Z, Ma X, Sung D, Li M, Kostì A, Lin G, et al. microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol. 2015;12(5):538–54.
24. Snaillings RL, Foley NH, Bray IM, Das S, Buckley PG. MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation. Semin Cancer Biol. 2011;21(4):283–90.
25. Mathay KK, Villablanca JG, Seeger RC, Strom DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341(16):1165–73.
26. Zhao Z, Partridge V, Souares M, Sheldon SD, Holland CL, Perstemidis A, et al. microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tuskushi. PLoS One. 2018;13(12):e0208777.
27. Du L, Schagenman JJ, Subaute MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-100, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009;7(8):1234–43.
28. Jan Koster RV, Danzy Zwingenburger, Piet Molenaar, Romeo Willinge Prins, Lieve Hoying, Rogier Versteeg, Jan Molenaar, Marcel Kool, Linda Valentinj. R2: Genomics analysis and visualization platform. https://r2.amc.nl. Accessed 1 Februal 2019.
29. Blis CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26(3):585–615.
30. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
31. Mathay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloblastic therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27(7):1007–13.
32. Veal GI, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, et al. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res. 2013;19(2):469–79.
33. Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010;17(5):497–509.
34. Janesick A, Wu SC, Blumberg B. Retinoic acid signaling and neuronal differentiation. Cell Mol Life Sci. 2015;72(9):1559–76.
35. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21(4):256–66.
36. Kas K, Voz ML, Hensen K, Meyen E, Van de Ven WJ. Transcriptional activation capacity of the novel PLAG family of zinc finger proteins. J Biol Chem. 1998;273(36):23026–32.
37. Kas K, Voz ML, Roijer E, Astrom AX, Meyen E, Steiman G, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet. 1997;15(2):170–4.
38. Abdollahi A, LOT1 (ZAC1/PLAGL1) and its family members: mechanisms and functions. J Cell Physiol. 2007;201(1):16–25.
39. Hensen K, Van Valkenborgh IC, Kas K, Van de Ven WJ, Voz ML. The tumorigenic diversity of the three PLAG family members is associated with different DNA binding capacities. Cancer Res. 2002;62(5):1510–21.
40. Declercq J, Hensen K, Van De Ven WJ, Chavez M. PLAG proteins: how they influence apoptosis and cell proliferation. Ann N Y Acad Sci. 2003;1004:264–5.
41. Landrette SF, Ruo YH, Hensen K, Barjesteh van Waaik van Doorn-Khosrowani S, Perrat PN, Van de Ven WJ, et al. Plag1 and Plag2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood. 2005;105(7):2900–7.
42. David S. Rickman, Johannes H. Schulte, Martin Eilers. The Expanding World of MYC–Driven Tumors. Cancer Discovery 2010;8(2):150–163.
stem cell fate and activates expression of ASCL2 in intestinal epithelial cells. Stem Cell Reports. 2018;11(2):410–24.

47. Landrette SF, Madera D, He F, Castilla LH. The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells. Leukemia 2011;25(4):655-662

48. Gang Zheng, Jinying Ning, Yu-Chung Yang. PLAGL2 controls the stability of Parh2, an E3 ubiquitin ligase for p53. Biochemical and Biophysical Research Communications. 2007;364(2):344-350

49. Su C, Li D, Li N, Du Y, Yang C, Bai Y, et al. Studying the mechanism of PLAGL2 overexpression and its carcinogenic characteristics based on 3′-untranslated region in colorectal cancer. Int J Oncol. 2018. https://doi.org/10.3892/ijo.2018.4305.

50. Wu L, Yuan W, Chen J, Zhou Z, Shu Y, Ji J, et al. Increased miR-214 expression suppresses cell migration and proliferation in Hirschsprung disease by interacting with PLAGL2. Pediatr Res. 2019;86(4):460–70.

51. Xu B, Zhang X, Wang S, Shi B. MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer. Pathol Res Pract. 2018;214(5):790–5.

52. Liu X, Chen X, Zeng K, Xu M, He B, Pan Y, et al. DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/beta-catenin signal pathways. Cell Death Dis. 2018;9(10):1037.

53. Zheng G, Yang YC. Sumoylation and acetylation play opposite roles in the transactivation of PLAG1 and PLAGL2. J Biol Chem. 2005;280(49):40773–81.

54. Ning J, Zheng G, Yang YC. Tip60 modulates PLAGL2-mediated transactivation by acetylation. J Cell Biochem. 2008;103(3):730–9.

55. Wezensky SJ, Hanks TS, Wilkison MJ, Ammons MC, Siemien DW, Gauss KA. Modulation of PLAGL2 transactivation by positive cofactor 2 (PC2), a component of the ARC/mediator complex. Gene. 2010;452(1):22–34.

56. Reynolds CP. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep. 2000;2(6):511–8.

57. Haussler M, Sidell N, Kelly M, Donaldson C, Altman A, Mangelsdorf D. Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines. Proc Natl Acad Sci U S A. 1983;80(18):5525–9.

58. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell. 1978;15(2):393–403.

59. Jetten AM, Jetten ME, Sherman ME. Stimulation of differentiation of several murine embryonal carcinoma cell lines by retinoic acid. Exp Cell Res. 1979;124(2):381–91.

60. Strickland S, Smith KK, Marotti KR. Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell. 1980;12(2):347–55.

61. Lotan R, Neumann G, Lotan D. Characterization of retinoic acid-induced alterations in the proliferation and differentiation of a murine and a human melanoma cell line in culture. Ann N Y Acad Sci. 1981;359:150–70.

62. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57(8):1000–4.

63. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst. 1982;68(4):589–96.

64. Lopez-Boado YS, Tolivia J, Lopez-Otin C. Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells. J Biol Chem. 1994;269(43):26871–8.

65. Arisi MF, Starker RA, Addya S, Huang Y, Fernandez SV. All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells. Int J Oncol. 2014;44(6):1831–42.

66. Zito G, Naselli F, Saieva I, Raimondo S, Calabrese G, Guzzardo C, et al. Retinoic acid affects lung adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition. Sci Rep. 2017;7(1):4770.